Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow CD34+ stem cells
- Development stage
- Phase 2
- Lead developer
- Emmes
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
This investigational autologous cell therapy consists of CD34+ stem cells isolated from a patient's own bone marrow for the treatment of vision loss associated with central retinal vein occlusion (CRVO). The therapy involves harvesting bone marrow aspirate, isolating the CD34+ progenitor cells using the Miltenyi CliniMACS system under Good Manufacturing Practice (GMP) conditions, and administering them via a single intravitreal injection. These stem cells are naturally occurring repair cells that migrate to sites of injury; in the context of CRVO, they are intended to home to the ischemic retina to promote vascular regeneration and provide paracrine trophic support to damaged retinal tissue. The therapy is currently being evaluated in a Phase I/II clinical trial (NCT02912403) sponsored by the National Eye Institute and coordinated by The Emmes Company, LLC in collaboration with the UC Davis Eye Center.
- Other names
- autologous CD34+ bone marrow stem cellsintravitreal autologous bone marrow CD34+ stem cell therapy
Beyond the preview
Go deeper on autologous bone marrow CD34+ stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow CD34+ stem cells.